SG11201900349VA - Somatostatin modulators and uses thereof - Google Patents

Somatostatin modulators and uses thereof

Info

Publication number
SG11201900349VA
SG11201900349VA SG11201900349VA SG11201900349VA SG11201900349VA SG 11201900349V A SG11201900349V A SG 11201900349VA SG 11201900349V A SG11201900349V A SG 11201900349VA SG 11201900349V A SG11201900349V A SG 11201900349VA SG 11201900349V A SG11201900349V A SG 11201900349VA
Authority
SG
Singapore
Prior art keywords
california
cornerstone
court
suite
international
Prior art date
Application number
SG11201900349VA
Inventor
Jian Zhao
Sangdon Han
Sun Hee Kim
Shimiao Wang
Yunfei Zhu
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201662362493P priority Critical
Priority to US201662411338P priority
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Priority to PCT/US2017/041694 priority patent/WO2018013676A1/en
Publication of SG11201900349VA publication Critical patent/SG11201900349VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#1110111101110101011111 vu 1101 0 0111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/013676 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7D 401/04 (2006.01) A61K 9/20 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/502 (2006.01) A61K 9/48 (2006.01) A61K 31/4725 (2006.01) Declarations under Rule 4.17: (21) International Application Number: — as to applicant's entitlement to apply for and be granted a PCT/US2017/041694 patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the (22) International Filing Date: earlier application (Rule 4.17(iii)) 12 July 2017 (12.07.2017) Published: (25) Filing Language: English — with international search report (Art. 21(3)) (26) Publication Language: English — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (30) Priority Data: amendments (Rule 48.2(h)) 62/362,493 14 July 2016 (14.07.2016) US 62/411,338 21 October 2016 (21.10.2016) US (71) Applicant: CRINETICS PHARMACEUTICALS, INC. [US/US]; 6197 Cornerstone Court, Suite 111, San Diego, California 92121 (US). (72) Inventors: ZHAO, Jian; 6197 Cornerstone Court, Suite _ 111, San Diego, California 92121 (US). HAN, Sangdon; 6197 Cornerstone Court, Suite 111, San Diego, California = 92121 (US). KIM, Sun Hee; 6197 Cornerstone Court, Suite 111, San Diego, California 92121 (US). WANG, Shimiao; =_ 6197 Cornerstone Court, Suite 111, San Diego, California 92121 (US). ZHU, Yunfei; 6197 Cornerstone Court, Suite 111, San Diego, California 92121 (US). Agent: ZUNIC, Valentin B.; Wilson Sonsini Goodrich & (74) = = Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 IN UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, M 1-1 O_ 0 (54) Title: SOMATOSTATIN MODULATORS AND USES THEREOF 1-1 0 (57) : Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical ei compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, 0 diseases, or disorders that would benefit from modulation of somatostatin activity.
SG11201900349VA 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof SG11201900349VA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201662362493P true 2016-07-14 2016-07-14
US201662411338P true 2016-10-21 2016-10-21
PCT/US2017/041694 WO2018013676A1 (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900349VA true SG11201900349VA (en) 2019-02-27

Family

ID=60941935

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900349VA SG11201900349VA (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Country Status (13)

Country Link
US (5) US9896432B2 (en)
EP (1) EP3484865A4 (en)
JP (1) JP2019520415A (en)
KR (1) KR20190026914A (en)
CN (1) CN109715612A (en)
AU (2) AU2017296392B2 (en)
BR (1) BR112019000692A2 (en)
CA (1) CA3030423A1 (en)
IL (1) IL264178D0 (en)
MX (1) MX2019000588A (en)
SG (1) SG11201900349VA (en)
TW (1) TW201805276A (en)
WO (1) WO2018013676A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013676A1 (en) * 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
BR112019019168A2 (en) 2017-03-16 2020-04-14 Crinetics Pharmaceuticals Inc somatostatin modulators and their uses
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3740475A4 (en) 2018-01-17 2021-06-09 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
MA51840A (en) * 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc SOMATOSTATIN MODULATORS AND THEIR USES
US20210246128A1 (en) * 2018-05-29 2021-08-12 Council Of Scientific & Industrial Research Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
WO2021011641A1 (en) * 2019-07-17 2021-01-21 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1035154A (en) 1910-05-16 1912-08-13 Ernest G Clark Machine for rectifying perforated music and masters.
FR2802206B1 (en) 1999-12-14 2005-04-22 Sod Conseils Rech Applic 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
AU2003205679B2 (en) * 2002-02-04 2006-06-29 F. Hoffmann-La Roche Ag Quinoline derivatives as NPY antagonists
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
WO2006017326A1 (en) * 2004-07-13 2006-02-16 Glaxo Group Limited Antibacterial agents
EP1996196A2 (en) * 2006-03-13 2008-12-03 Merck & Co., Inc. Somatostatin agonists
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
KR101826382B1 (en) 2010-07-30 2018-02-06 온코세라피 사이언스 가부시키가이샤 Quinoline derivatives and melk inhibitors containing the same
CN103917525B (en) 2011-05-23 2016-08-17 依兰制药公司 The inhibitor of LRRK2 kinase activity
EP2763675A2 (en) 2011-10-05 2014-08-13 Mapi Pharma Limited Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
EP2871179A4 (en) * 2012-07-03 2016-03-16 Ono Pharmaceutical Co Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
AU2013331505A1 (en) * 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
CA2925651A1 (en) * 2013-09-30 2015-04-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2018013676A1 (en) * 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3740475A4 (en) 2018-01-17 2021-06-09 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators

Also Published As

Publication number Publication date
EP3484865A4 (en) 2019-12-25
AU2020277122A1 (en) 2020-12-24
US20180016252A1 (en) 2018-01-18
US10875839B2 (en) 2020-12-29
AU2017296392B2 (en) 2020-09-24
KR20190026914A (en) 2019-03-13
US20190382367A1 (en) 2019-12-19
IL264178D0 (en) 2019-02-28
TW201805276A (en) 2018-02-16
US10351547B2 (en) 2019-07-16
CN109715612A (en) 2019-05-03
AU2017296392A1 (en) 2019-02-28
US20210171492A1 (en) 2021-06-10
US20190002431A1 (en) 2019-01-03
JP2019520415A (en) 2019-07-18
MX2019000588A (en) 2019-09-09
EP3484865A1 (en) 2019-05-22
US9896432B2 (en) 2018-02-20
BR112019000692A2 (en) 2019-04-24
WO2018013676A1 (en) 2018-01-18
US10597377B2 (en) 2020-03-24
CA3030423A1 (en) 2018-01-18
US20200190053A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201804587QA (en) Isoindole compounds
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201908226XA (en) Rapamycin analog